Search results for "Cancer development"

showing 10 items of 30 documents

Depleted uranium induces human carcinogenesis involving the immune and chaperoning systems: Realities and working hypotheses

2019

Abstract Cancer is caused by a combination of factors, genetic, epigenetics and environmental. Among the latter, environmental pollutants absorbed by contact, inhalation, or ingestion are major proven or suspected culprits. Depleted uranium (DU) is one of them directly pertinent to the military and civilians working in militarized areas. It is considered a weak carcinogen but its implication in cancer development in exposed individuals is supported by various data. Since not all subjects exposed to DU develop cancer, it is likely that DU-dependent carcinogenesis requires cofactors, such as genetic predisposition and deficiencies of the chaperoning and immune systems. It is of the essence to…

0301 basic medicineNeoplasms Radiation-InducedCarcinogenesisNatural killer cellPreventive measureWorking hypothesisBioinformaticsmedicine.disease_causeRisk AssessmentEpigenesis Genetic03 medical and health sciences0302 clinical medicineImmune systemOccupational ExposureGenetic predispositionmedicineHumansBone marrowDepleted uraniumSkinAir PollutantsChaperoning systemCarcinogenic cofactorbusiness.industryGenetic predispositionMicrobiotaMedicine (all)CancerEnvironmental ExposureGeneral MedicineArmed ConflictsModels Theoreticalmedicine.diseaseEnvironmental pollutantMilitary PersonnelImmune system030104 developmental biologyCarcinogensMolecular chaperoneUraniumEnvironmental PollutantsCancer developmentCarcinogenesisbusiness030217 neurology & neurosurgeryMolecular ChaperonesMedical Hypotheses
researchProduct

Female-specific association among I, J and K mitochondrial genetic haplogroups and cancer:A longitudinal cohort study

2018

Recent studies highlighted the role of mitochondrial dysregulation in cancer, suggesting that the different mitochondrial haplogroups might play a role in tumorigenesis and risk of cancer development. Our aim is to investigate whether any mitochondrial haplogroups carried a significant higher risk of cancer development in a large prospective cohort of North American people. The haplogroup assignment was performed by a combination of sequencing and PCR-RFLP techniques. Our specific outcome of interest was the incidence of any cancer during follow-up period. Overall, 3222 participants were included in the analysis. Women having I, J, K haplogroup reported a significant higher incidence of can…

0301 basic medicineOncologyCancer Researchmedicine.medical_specialtygenetic structuresBiologymedicine.disease_causeDNA MitochondrialHaplogroupHaplogroupArticleCohort Studies03 medical and health sciences0302 clinical medicineInternal medicineNeoplasmsGeneticsmedicineHumansGenetic Predisposition to DiseaseLongitudinal StudiesLongitudinal cohortProspective cohort studyMolecular BiologyOncogenesisCancerCancer Screening Oncogenesis Mitochondrial HaplogroupIncidence (epidemiology)Cancermedicine.diseaseeye diseaseshumanitiesMitochondrial030104 developmental biologyHaplotypes030220 oncology & carcinogenesisScreeningCancer; Haplogroup; Mitochondrial; Oncogenesis; ScreeningFemaleCancer developmentCarcinogenesis
researchProduct

ESMO consensus guidelines for the management of patients with metastatic colorectal cancer

2016

Contains fulltext : 165965.pdf (Publisher’s version ) (Closed access) Colorectal cancer (CRC) is one of the most common malignancies in Western countries. Over the last 20 years, and the last decade in particular, the clinical outcome for patients with metastatic CRC (mCRC) has improved greatly due not only to an increase in the number of patients being referred for and undergoing surgical resection of their localised metastatic disease but also to a more strategic approach to the delivery of systemic therapy and an expansion in the use of ablative techniques. This reflects the increase in the number of patients that are being managed within a multidisciplinary team environment and speciali…

0301 basic medicineOncologymedicine.medical_specialtyEvidence-based practiceBevacizumabColorectal cancerCancer development and immune defence Radboud Institute for Molecular Life Sciences [Radboudumc 2]Guidelines as Topiccolorectal cancerRare cancers Radboud Institute for Molecular Life Sciences [Radboudumc 9]03 medical and health scienceschemistry.chemical_compoundClinical practice guidelines; Colorectal cancer; Consensus; ESMO; Hematology; Oncology0302 clinical medicineGuia de Práctica ClínicaInternal medicineBiomarkers TumormedicineHumansMolecular Targeted TherapyNeoplasm MetastasisIntensive care medicineTipiracilNeoplasias Colorrectais/tratamentoFOLFOXIRIbusiness.industryESMO; clinical practice guidelines; colorectal cancer; consensusCancerHematologyESMOPrognosismedicine.diseaseDebulkingChemotherapy regimendigestive system diseases3. Good health030104 developmental biologyPractice GuidelineOncologychemistryColorectal Neoplasms/therapyconsensus030220 oncology & carcinogenesisColorectal Neoplasmsbusinessclinical practice guidelinesclinical practice guidelinemedicine.drug
researchProduct

Development of an RNA-based kit for easy generation of TCR-engineered lymphocytes to control T-cell assay performance.

2018

Cell-based assays to monitor antigen-specific T-cell responses are characterized by their high complexity and should be conducted under controlled conditions to lower multiple possible sources of assay variation. However, the lack of standard reagents makes it difficult to directly compare results generated in one lab over time and across institutions. Therefore TCR-engineered reference samples (TERS) that contain a defined number of antigen-specific T cells and continuously deliver stable results are urgently needed. We successfully established a simple and robust TERS technology that constitutes a useful tool to overcome this issue for commonly used T-cell immuno-assays. To enable users t…

0301 basic medicineRNA StabilityComputer scienceT cellPerformanceCancer development and immune defence Radboud Institute for Molecular Life Sciences [Radboudumc 2]RNA StabilityT-LymphocytesImmunologyCell Culture TechniquesComputational biology03 medical and health sciences0302 clinical medicineAll institutes and research themes of the Radboud University Medical CenterHigh complexityValidationHLA-A2 AntigenmedicineImmunology and AllergyHumansImrnunoguidingRNA MessengerCell EngineeringT-cell assaysReceptors Chimeric AntigenImmunomagnetic SeparationElectroporationT-cell receptorRNAReference StandardsStandardizationImmunomonitoring030104 developmental biologymedicine.anatomical_structureElectroporationBlood Buffy CoatFeasibility StudiesBiological Assay030215 immunologyJournal of immunological methods
researchProduct

Ageing: from inflammation to cancer.

2018

Abstract Ageing is the major risk factor for cancer development. Hallmark of the ageing process is represented by inflammaging, which is a chronic and systemic low-grade inflammatory process. Inflammation is also a hallmark of cancer and is widely recognized to influence all cancer stages from cell transformation to metastasis. Therefore, inflammaging may represent the biological phenomena able to couple ageing process with cancer development. Here we review the molecular and cellular pathway involved in age-related chronic inflammation along with its potential triggers and their connection with cancer development.

0301 basic medicineSenescencelcsh:Immunologic diseases. AllergyAgingCellImmunologyAgeing; Cancer; DAMPs; Inflammation; MiRna; Microbiota; Obesity; SenescenceInflammationReviewlcsh:GeriatricsSenescenceMetastasis03 medical and health sciencesmicroRNAMedicineDAMPObesityCancerSettore MED/04 - Patologia GeneraleInflammationDAMPsbusiness.industryAgeing; Cancer; DAMPs; Inflammation; Microbiota; MiRna; Obesity; Senescence; Immunology; AgingMicrobiotaCancermedicine.diseaselcsh:RC952-954.6Ageing030104 developmental biologymedicine.anatomical_structureAgeingCancer researchSettore MED/26 - NeurologiaCancer developmentmedicine.symptombusinesslcsh:RC581-607MiRna
researchProduct

Smart inulin-based polycationic nanodevices for siRNA delivery

2017

The advances of short interfering RNA (siRNA) mediated therapy provide a powerful option for the treatment of many diseases by silencing the expression of targeted genes including cancer development and progression. Inulin is a very simple and biocompatible polysaccharide proposed by our groups to produce interesting delivery systems for Nucleic Acid Based Drugs (NABDs), such as siRNA, either as polycations able to give polyplexes and polymeric coatings for nanosystems having a metallic core. In this research field, different functionalizing groups were linked to the inulin backbone with specific aims including oligoamine such as Ethylendiammine (EDA), Diethylediamine (DETA), Spermine, (SPM…

3003Small interfering RNABiocompatibilitysiRNA complexing abilityInulinPharmaceutical ScienceSpermineNanotechnology02 engineering and technology010402 general chemistry01 natural scienceschemistry.chemical_compoundDrug Delivery SystemsPolyaminesBiocompatibility; Silencing ability; siRNA complexing ability; 3003HumansNanotechnologyGene silencingRNA Small InterferingChemistryInulin021001 nanoscience & nanotechnologyPolyelectrolytes0104 chemical sciencesBiochemistryNucleic acidBiocompatibilityCancer development0210 nano-technologySilencing abilityChemical design
researchProduct

Improved relapse-free survival after autologous stem cell transplantation does not translate into better quality of life in chronic lymphocytic leuke…

2014

Item does not contain fulltext In chronic lymphocytic leukemia (CLL) medical progress is driven by clinical studies with relapse-free survival (RFS) as the primary endpoint. The randomized EBMT-Intergroup trial compared high-dose therapy and autologous stem cell transplantation (ASCT) to observation and demonstrated a substantial improvement of RFS without showing improved overall survival for the transplant arm. Here we report quality of life (QoL) information of the first 3 years following randomization from that study. The main objective was to assess the impact of treatment on QoL over time. Two secondary analyses were performed to further investigate the impact of ASCT and relapse on Q…

AdultMaleOncologymedicine.medical_specialtyTransplantation ConditioningRandomizationCancer development and immune defence Radboud Institute for Molecular Life Sciences [Radboudumc 2][SDV]Life Sciences [q-bio]medicine.medical_treatmentChronic lymphocytic leukemiaHematopoietic stem cell transplantationTransplantation Autologous03 medical and health sciences0302 clinical medicineAutologous stem-cell transplantationQuality of lifeRecurrenceSurveys and QuestionnairesInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineClinical endpointHumansComputingMilieux_MISCELLANEOUSAgedbusiness.industryHematopoietic Stem Cell TransplantationHematologyMiddle Agedmedicine.diseaseLeukemia Lymphocytic Chronic B-Cellhumanities3. Good healthSurgeryTransplantation030220 oncology & carcinogenesisQuality of LifeFemaleTransplantation Conditioningbusiness030215 immunologyAmerican Journal of Hematology
researchProduct

Safety and Activity of the First-in-Class Sym004 Anti-EGFR Antibody Mixture in Patients with Refractory Colorectal Cancer

2015

Abstract Tumor growth in the context of EGFR inhibitor resistance may remain EGFR-dependent and is mediated by mechanisms including compensatory ligand upregulation and de novo gene alterations. Sym004 is a two-antibody mixture targeting nonoverlapping EGFR epitopes. In preclinical models, Sym004 causes significant EGFR internalization and degradation, which translates into superior growth inhibition in the presence of ligands. In this phase I trial, we observed grade 3 skin toxicity and hypomagnesemia as mechanism-based dose-limiting events during dose escalation. In dose-expansion cohorts of 9 and 12 mg/kg of Sym004 weekly, patients with metastatic colorectal cancer and acquired EGFR inhi…

AdultMaleProto-Oncogene Proteins B-rafClass I Phosphatidylinositol 3-KinasesColorectal cancerCancer development and immune defence Radboud Institute for Molecular Life Sciences [Radboudumc 2]Antineoplastic AgentsContext (language use)Rare cancers Radboud Institute for Molecular Life Sciences [Radboudumc 9]LigandsPhosphatidylinositol 3-Kinaseschemistry.chemical_compoundCell Line TumorHumansMedicinePanitumumabNeoplasm MetastasisAgedEGFR inhibitorsAged 80 and overDose-Response Relationship DrugCetuximabbusiness.industryGene AmplificationAntibodies MonoclonalCancerMiddle Agedmedicine.diseaseErbB ReceptorsClinical trialGenes rasTreatment OutcomeOncologychemistryMutationImmunologyCancer researchFemaleGrowth inhibitionColorectal Neoplasmsbusinessmedicine.drug
researchProduct

PLGA Nanoparticles Co-encapsulating NY-ESO-1 Peptides and IMM60 Induce Robust CD8 and CD4 T Cell and B Cell Responses

2021

Contains fulltext : 232076.pdf (Publisher’s version ) (Open Access) Tumor-specific neoantigens can be highly immunogenic, but their identification for each patient and the production of personalized cancer vaccines can be time-consuming and prohibitively expensive. In contrast, tumor-associated antigens are widely expressed and suitable as an off the shelf immunotherapy. Here, we developed a PLGA-based nanoparticle vaccine that contains both the immunogenic cancer germline antigen NY-ESO-1 and an α-GalCer analog IMM60, as a novel iNKT cell agonist and dendritic cell transactivator. Three peptide sequences (85-111, 117-143, and 157-165) derived from immunodominant regions of NY-ESO-1 were se…

CD4-Positive T-Lymphocyteslcsh:Immunologic diseases. AllergyCancer development and immune defence Radboud Institute for Molecular Life Sciences [Radboudumc 2]T cellmedicine.medical_treatment[SDV]Life Sciences [q-bio]ImmunologyCD8-Positive T-Lymphocyteschemistry.chemical_compoundPolylactic Acid-Polyglycolic Acid CopolymerAntigenmedicinepeptide vaccineHumansImmunology and AllergyCytotoxic T cellNY-ESO-1B cellOriginal ResearchB-LymphocytesDrug CarriersDendritic cellImmunotherapyCD4 T cellPLGA nanoparticleIMM60Peptide FragmentsNeoplasm Proteins[SDV] Life Sciences [q-bio]PLGAmedicine.anatomical_structurechemistryCD8 T cellCancer researchB cell epitopeiNKT cellNanoparticleslcsh:RC581-607CD8
researchProduct

EURECCA colorectal: multidisciplinary management: European consensus conference colon & rectum.

2014

Contains fulltext : 137861.pdf (Publisher’s version ) (Closed access) BACKGROUND: Care for patients with colon and rectal cancer has improved in the last 20years; however considerable variation still exists in cancer management and outcome between European countries. Large variation is also apparent between national guidelines and patterns of cancer care in Europe. Therefore, EURECCA, which is the acronym of European Registration of Cancer Care, is aiming at defining core treatment strategies and developing a European audit structure in order to improve the quality of care for all patients with colon and rectal cancer. In December 2012, the first multidisciplinary consensus conference about…

Cancer ResearchQuality Assurance Health CareColorectal cancerCancer development and immune defence Radboud Institute for Molecular Life Sciences [Radboudumc 2]Delphi methodSurgical oncologyFAMILIAL ADENOMATOUS POLYPOSISTumours of the digestive tract Radboud Institute for Molecular Life Sciences [Radboudumc 14]MedicineSHORT-COURSE RADIOTHERAPYRectal cancerQuality assurance; Colon cancer; Rectal cancer; Multidisciplinary teams; Consensus; Delphi method; Audit; Neoadjuvant treatment; Adjuvant treatment; SurgerySettore MED/36 - DIAGNOSTICA PER IMMAGINI E RADIOTERAPIADisease ManagementPHASE-III TRIALRANDOMIZED CONTROLLED-TRIALNeoadjuvant TherapyQuality assuranceColon cancerEuropemedicine.anatomical_structureTreatment OutcomeOncologyTRANSANAL ENDOSCOPIC MICROSURGERYColonic NeoplasmsPractice Guidelines as TopicHYPERTHERMIC INTRAPERITONEAL CHEMOTHERAPYmedicine.medical_specialtyNeoadjuvant treatmentEvidence-based practiceConsensusLYMPH-NODE EVALUATIONDelphi methodRectumAuditSDG 3 - Good Health and Well-beingHumansCIRCUMFERENTIAL RESECTION MARGINddc:610business.industryRectal NeoplasmsTOTAL MESORECTAL EXCISIONCancerLONG-TERM SURVIVALAuditAdjuvant treatmentmedicine.diseaseSurgeryOncology nursingFamily medicineSurgeryMultidisciplinary teamsbusiness
researchProduct